大健康政策背景下药品医保全生命周期管理研究综述

doi:10.3969/j.issn.1003-2800.2022.05.004

PDF(606 KB)

卫生软科学 ›› 2022, Vol. 36 ›› Issue (5) : 17-21. DOI: 10.3969/j.issn.1003-2800.2022.05.004

聚焦医改

大健康政策背景下药品医保全生命周期管理研究综述

郑淇¹, 林春盛², 关欣¹, 耿欣¹

作者信息 +

The research review on full life cycle management of medical insurance for drug under the background of comprehensive health

ZHENG Qi¹, LIN Chun-sheng², GUAN Xin³, GENG Xin¹

Author information +

文章历史 +

摘要

分析了国外部分国家药价制定方法和标准、医保遴选标准及专家准入机制、药价谈判协作模式及系统性。结合我国国家医疗保障局成立后,药品价格管理与医保药品目录管理中存在的问题,总结当前“药品医保全生命周期”3个方面的研究现状,从加强对医保目录全流程管理、建立实证研究和模型分析、丰富退出机制、建立医保药品价格谈判协调机制等7方面对今后我国的医保工作及研究提出了对策建议。

Abstract

Analyze the methods and standards of drug price formulation,medical insurance selection standards and expert access mechanism,and drug price negotiation and cooperation model and system in foreign countries. Combine with problems in drug price management and medical insurance drug catalog management after the establishment of The National Healthcare Security Administration of China. This paper analyzes the current research status in three aspects of the“whole life cycle of drug medical insurance”. Countermeasures and suggestions are put forward from seven aspects,including strengthening the whole process management of medical insurance catalogue,establishing empirical research and model analysis,enriching withdrawal mechanism and establishing price negotiation and coordination mechanism of medical insurance drugs and so on. In order to find out the way for further medical insurance working and research in China.

导出引用

郑淇, 林春盛, 关欣, 耿欣. 大健康政策背景下药品医保全生命周期管理研究综述[J]. 卫生软科学, 2022, 36(5): 17-21 https://doi.org/10.3969/j.issn.1003-2800.2022.05.004

ZHENG Qi, LIN Chun-sheng, GUAN Xin, GENG Xin. The research review on full life cycle management of medical insurance for drug under the background of comprehensive health[J]. Soft Science of Health, 2022, 36(5): 17-21 https://doi.org/10.3969/j.issn.1003-2800.2022.05.004

参考文献

[1] 黄自发,季旭,鲁翔.新医改下对国家基本药物指导价的药物经济学研究[J].中国卫生经济,2010,29(4):88-90.
[2] EON VAN DER MERWE SMIT,JHANDR BREDENKAMP.Originator and Generic Medicine:Pricing and Market Share[J].International Journal of Pharmaceutical and Healthcare Marketing,2013,7(2):104-119.
[3] BACH,PETER B PEARSON,STEVEN D.Payer and Policy Maker Steps to Support Value-Based Pricing for Drugs[J].JAMA:the Journal of the American Medical Association,2015,314(23):2503-2504.
[4] LOUIS P GARRISON JR,ADRIAN TOWSE.Value-Based Pricing and Reimbursement in Personalised Healthcare:Introduction to the Basic Health Economics[J].Journal of Personalized Medicine,2017(7):1-10.
[5] KALTENBOECK,ANNA,BACH,et al.Value-Based Pricing for Drugs Theme and Variations[J].JAMA:the Journal of the American Medical Association,2018,319(21):2165-2166.
[6] PARK SUN-YOUNG,HAN EUNA,KIM JINI,et al.Factors Influencing the Difference between Forecasted and Actual Drug Sales Volumes under the Price-volume Agreement in South Korea[J].Health Policy,2016,120(8):867-874.
[7] 颜建周,董心月,马旭锋,等.英国价值定价理念对我国医保药品报销政策的启示[J].中国卫生政策研究,2020,13(1):62-69.
[8] 丁锦希,黄泽华,钭江苑.澳大利亚专利药价格谈判制度实证研究与启示[J].中国卫生经济,2016,35(12):116-119.
[9] 杨姿锐,陶田甜,蒋蓉,等.澳大利亚医保药品价格协议研究及对我国的启示[J].中国卫生经济,2020,39(6):93-96.
[10] 牛瑞,刘影,向玉芳,等.药品价格谈判国际经验与国内实践的比较研究[J].中国卫生政策研究,2017,10(6):25-32.
[11] 伍琳,陈佳妮,雷媛,等.构建专利药价格谈判利益平衡机制的路径选择 ——基于德国、英国、韩国等典型国家药价谈判机制的启示[J].价格理论与实践,2018(3):83-86.
[12] 陶田甜,黄秋雨,侯立丽,等.加拿大、澳大利亚专利药谈判模式对我国的启示[J].中国卫生资源,2019,22(5):391-396.
[13] 沈洪涛,梁雪峰.中欧药品价格构成比较与对策建议[J].中国卫生政策研究,2020,13(7):46-51.
[14] 陈蕾,冷明祥,胡大洋,等.澳大利亚医保目录的药品准入谈判对我国的启示[J].南京医科大学学报(社会科学版),2011(5):364-367.
[15] 胡颖廉.产业安全和质量安全:中国药品监管体制改革的逻辑[J].社会科学战线,2016(7):207-215.
[16] SALAS-VEGA,SEBASTIAN,BERTLING ANNIKA,et al.A Comparative Study of Drug Listing Recommendations and the Decision-making Process in Australia,the Netherlands,Sweden,and the UK[J].Health policy,2016,120(10):1104-1114.
[17] 张霄艳,张晓娜.2017版《医保目录》下对我国医保目录管理的思考[J].当代经济,2018(6):124-125.
[18] 朱越,蒋蓉,邵蓉.澳大利亚药品注册与医保准入并行程序研究[J].中国卫生经济,2018,37(11):89-92.
[19] 赵华婷,颜建周,邵蓉.德国临床效益评估对我国创新药医保准入临床价值评价的启示[J].中国新药杂志,2019,28(19):2323-2326.
[20] 李赛赛,徐伟,王煜昊,等.创新药物医保目录准入研究[J].卫生经济研究,2019,36(10):40-43.
[21] 丁锦希,韩秋喜,陈烨,等.医保准入中同类药品与参照药物对比研究[J].中国医疗保险,2020(5):36-40.
[22] RAYMOND C HUTUBESSY,ROB M BALTUSSEN,TESSA TAN TORRES-EDEJER,et al.Generalised Cost-effectiveness Analysis:An Aid to Decision Making in Health[J].Applied Health Economics and Health Policy,2002,1(2):89-95.
[23] MATHIAS FLUME,MARC BARDOU,STEFANO CAPRI,et al.Approaches to Manage Affordability of High Budget Impact Medicines in Key EU Countries[J].Journal of Market Access& Health Policy,2018,6(1):1478539.
[24] 王敏娇,王文,柳鹏程.医保谈判准入中药物经济学和可负担性研究及其测量工具的运用[J].中国药物经济学,2020,15(8):5-8,13.
[25] 李轶.成本-效果阈值在医保准入决策中的应用[J].中国药物经济学,2020,15(9):30-35.
[26] SERMET CATHERINE,ANDRIEU VERONIQUE,GODMAN BRIAN,et al.Ongoing Pharmaceutical Reforms in France:Implications for Key Stakeholder Groups[J].Applied Health Economics and Health Policy,2010,8(1).7-24.
[27] 吴久鸿,王翔,赵绯丽.澳大利亚医保目录动态调整机制管理经验及启示[J].中国卫生经济,2018,37(9):94-96.
[28] 姚嘉奇,周挺,管欣,等.英国 NICE 卫生技术评估介绍及对我国医保目录动态调整的启示[J].中国循证医学杂志,2018,18(9):984-989.
[29] 王煜昊,徐伟,李赛赛,等.日本医保药品目录动态调整机制研究及对我国的启示[J].中国卫生经济,2019,38(9):93-96.
[30] 周若婧,江滨.费用上涨全球难题何解？德国医保控费这么做[N].医药经济报,2020-09-24(003).
[31] 吴久鸿,赵绯丽,岳晓萌,等.《基本医疗保险用药管理暂行办法》:动态调整之退出机制思考[J].世界临床药物,2020(8):629-632.
[32] 王亮,岳晓萌,李钰翔,等.中日医保药品目录管理差异与思考:日本医保目录动态调整机制之启示[J].中国卫生经济,2020,39(5):91-96.
[33] 吕兰婷,余浏洁.利益相关方在英国药品目录动态调整中的参与机制[J].中国医疗保险,2020(3):76-80.
[34] HENSCHKE C,SUNDMACHER L,BUSSE R.Structural Changes in the German Pharmaceutical Market:Price Setting Mechanisms Based on the Early Benefit Evaluation[J].Health Policy,2013,109(3):263-269.
[35] 刘浩然,汤少梁.信息不对称条件下医疗服务市场主体间的博弈关系分析[J].医学与社会,2016,29(4):14-16,23.
[36] 刘长玉,于涛,马英红.基于产品质量监管视角的政府、企业与消费者博弈策略研究[J].中国管理科学,2019(4):127-135.
[37] 于涛,刘长玉.政府与第三方在产品质量监管中的演化博弈分析及仿真研究[J].中国管理科学,2016(6):90-96.
[38] 贾琼,许丰,吴海波.基于博弈论的医保支付方式最优选择研究[J].医学与社会,2020,33(2):112-116.
[39] 张新鑫,侯文华,申成霖.价格管制、战略性创新激励与创新药市场绩效[J].科研管理,2017(10):68-75.

基金

黑龙江省哲学社会科学研究规划项目(19ZXE253)

PDF(606 KB)

2367

Accesses

Citation

Detail

段落导航

摘要
Abstract
关键词
Key words
引用本文
参考文献
基金

收稿日期	出版日期
2022-03-15	2022-05-15
发布日期
2022-05-16

选择文件类型/文献管理软件名称

选择包含的内容

摘要

Abstract

关键词

Key words

引用本文

{{custom_sec.title}}

{{custom_sec.title}}

参考文献

{{custom_fnGroup.title_cn}}

脚注

基金

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

摘要

Abstract

关键词

Key words

引用本文

{{custom_sec.title}}

{{custom_sec.title}}

参考文献

{{custom_fnGroup.title_cn}}

脚注

基金